Short Communication: Comparative Evaluation of Coformulated Injectable Combination Antiretroviral Therapy Regimens in Simian Immunodeficiency Virus-Infected Rhesus Macaques

AIDS Research and Human Retroviruses

Volumn 32, Issue 2, 2016, Pages 163-168

  Del Prete, Gregory Q ^a   Smedley, Jeremy ^a   Macallister, Rhonda ^a,c   Jones, Gregg S ^b   Li, Bei ^b   Hattersley, Jillian ^b   Zheng, Jim ^b   Piatak, Michael ^a,d   Keele, Brandon F ^a   Hesselgesser, Joseph ^b   Geleziunas, Romas ^b   Lifson, Jeffrey D ^a  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^b GILEAD SCIENCES   (United States)

^c Washington National Primate Research Center   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR; DOLUTEGRAVIR; EMTRICITABINE; RITONAVIR; TENOFOVIR DISOPROXIL; VIRUS RNA; ANTIRETROVIRUS AGENT; DRUG COMBINATION; FUSED HETEROCYCLIC RINGS; INTEGRASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ADD ON THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL RESISTANCE; ARTICLE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONCENTRATION AT STEADY-STATE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SUBSTITUTION; EARLY INTERVENTION; FEASIBILITY STUDY; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; MAINTENANCE DRUG DOSE; MONOTHERAPY; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; REBOUND; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SINGLE DRUG DOSE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIROLOGY; VIRUS LOAD; ANIMAL; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS;

ANIMALS; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG COMBINATIONS; DRUG RESISTANCE, VIRAL; EMTRICITABINE; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INTEGRASE INHIBITORS; MACACA MULATTA; REVERSE TRANSCRIPTASE INHIBITORS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TENOFOVIR; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84958974351     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2015.0130     Document Type: Article

References (20)

1. Del Prete GQ, Lifson JD. Considerations in the development of nonhuman primate models of combination antiretroviral therapy for studies of AIDS virus suppression, residual virus, and curative strategies. Curr Opin HIV AIDS 2013;8(4):262-272.
2. Shytaj IL, Norelli S, Chirullo B, et al.: A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model. PLoS Pathog 2012;8(6):e1002774.
3. Lewis MG, DaFonseca S, Chomont N, et al.: Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension. AIDS 2011;25(11):1347-1356.
4. Ling B, Piatak M, Jr., Rogers L, et al.: Effects of treatment with suppressive combination antiretroviral drug therapy and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) on SIV-infected Chinese rhesus macaques. PLoS One 2014;9(7):e102795.
5. Del Prete GQ, Shoemaker R, Oswald K, et al.: Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected Indian rhesus macaques. Antimicrob Agents Chemother 2014;58(11):6790-6806.
6. Keele BF, Li H, Learn GH, et al.: Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med 2009;206(5):1117-1134.
7. de Meyer S, Vangeneugden T, van Baelen B, et al.: Resistance profile of darunavir: Combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses 2008;24(3): 379-388.
8. Forthal DN, Landucci G, Cole KS, et al.: Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells. J Virol 2006;80(18): 9217-9225.
9. Whitney JB, Hill AL, Sanisetty S, et al.: Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 2014;512(7512):74-77.
10. Lewis MG, Norelli S, Collins M, et al.: Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: A basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology 2010;7:21.
11. Van Rompay KK, Durand-Gasselin L, Brignolo LL, et al.: Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: Summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother 2008;52(9):3144-3160.
12. Sanders-Beer BE, Spano YY, Golighty D, et al.: Clinical monitoring and correlates of nephropathy in SIV-infected macaques during high-dose antiretroviral therapy. AIDS Res Ther 2011;8(1):3.
13. Deeks SG, Barditch-Crovo P, Lietman PS, et al.: Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl]adenine, a novel antihuman immunodeficiency virus (HIV) therapy, in HIVinfected adults. Antimicrob Agents Chemother 1998;42(9): 2380-2384.
14. Barditch-Crovo P, Deeks SG, Collier A, et al.: Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001;45(10):2733-2739.
15. Morcock DR, Thomas JA, Sowder RC, 2nd, et al.: HIV-1 inactivation by 4-vinylpyridine is enhanced by dissociating Zn(2+) from nucleocapsid protein. Virology 2008;375(1): 148-158.
16. Del Prete GQ, Park H, Fennessey CM, et al.: Molecularly tagged simian immunodeficiency virus SIVmac239 synthetic swarm for tracking independent infection events. J Virol 2014;88(14):8077-8090.
17. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: Clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 2004;43(9):595-612.
18. Durand-Gasselin L, Van Rompay KK, Vela JE, et al.: Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys. Mol Pharm 2009;6(4):1145-1151.
19. Song I, Borland J,Min S, et al.: Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir. Antimicrob Agents Chemother 2011;55(7):3517-3521.
20. Song I, Min SS, Borland J, et al.: The effect of lopinavir/ ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants. J Clin Pharmacol 2011;51(2):237-242.